Starpharma (ASX:SPL) has seen positive results with targeted DEO using antibody fragment in human ovarian cancer model.
Treatment with a novel HER-2 targeted DEP resulted in tumour regression and 100 per cent survival in the experiment.
This experiment used a novel antibody fragment, which, like a whole antibody, binds actively and selectively to a specific antigen.
Using antibody fragments instead of full-sized antibodies has a number of commercial and technical benefits which stem from their small size, high potency, stability and ease of manufacture.
Shares in Starpharma (ASX:SPL) are trading 1.82 per cent higher at $1.12.